

PROVIDER FORUM NOTIFICATION & INVITATION

November 29, 2022

To: Providers, Staff and Billing Staff From: Care1st Network Management

You are invited to join Care1st as we present the RBHA Post Go-Live Implementation & 12/1/22 System Integration Provider Forum:

The Forum topics will include:

- Care1st Regional Behavioral Health Authority (RBHA) Implementation follow up
- 12/1/22 System Integration
 - o Claims Address Changes
 - o Payor ID Changes
 - o PaySpan Registration
 - o Provider Portal Registration
- Electronic Visit Verification (EVV) Hard Edits (starting January 1, 2023)
- Claims Trends

Experts from multiple departments will be in attendance to share valuable information regarding the ACC and RBHA programs. All contracted providers and staff are encouraged to attend. Please register for our virtual session by completing the forum attached.

Date and Time	Location		
Thursday, December, 8 2022	Virtually via Zoom		
10:00 am – 12:00 pm	(Registration required to receive zoom link)		

Thank you!

Care1st Network Management
Ph 866.560.4042 (Options in order: 5, 7)
Fax 833-618-1507/E-mail SM_AZ_PNO@Care1stAZ.com



TO RSVP PLEASE COMPLETE THE INFORMATION BELOW AND SUBMIT BY FAX OR EMAIL

Fax: 602-224-4365Email: sm az pno@care1staz.com

Email (Please Print)	
	Email (Please Print)

Care1st Network Management
Ph 866.560.4042 (Options in order: 5, 7)
Fax 833-618-1507/E-mail SM_AZ_PNO@Care1stAZ.com



FORMULARY UPDATES Effective 1/01/2023

November 29, 2022

Dear Care1st Providers and Staff:

Effective January 1, 2023, Care1st will implement the AHCCCS formulary changes based on the recommendations from the October 19, 2022, AHCCCS Pharmacy & Therapeutics (P & T) Committee. To review the Care1st Preferred Drug Lists including the recent updates, visit our website at:

www.care1staz.com > For Providers > Pharmacy > Preferred Drug Lists

Care1st encourages all prescribing clinicians to review the Care1st Preferred Drug Lists (PDL) for preferred formulary alternatives prior to prescribing. The table below highlights some of the upcoming Formulary changes.

Drug Class	Drug (s) Removed from Formulary	Preferred Alternative(s) on Formulary (NEW or current alternatives)	Utilization Management (PA, STEP, QL, AGE)**	*Grandfathering permitted (Y/N)
Antifungals, Oral	N/A	Vfend (Oral Suspension)	QL	N
Calcium Channel Blockers	N/A	Katerzia (amlodipine Oral Sus pension)	PA required for ages > 7 years old	N
HIV/AIDS	 Crixivan Viracept Invirase Tablets Stavudine Capsules 	 Symfi (Oral Suspension) Symfi Lo (Oral Suspension) Triumeq (Tablets and Oral Suspension) 	N/A	Y *Except for Icatibant which is the generic of Firazyr.
Hereditary Angioedema Agents	 Icatibant Takhzyro Vial Takhzyro Syringes Haegarda Ruconest 	 Cinryze (Intravenous) Berinert (Intravenous) Firazyr (Subcutaneous) Kalbitor (Subcutaneous) Orladeyo (Oral Suspension) 	PA	Υ
Immunomodulators	 Elidel (Topical) Protopic (Topical) Opzelura (Topical) Adbry (Subcuta neous) 	 Tacrolimus (AG) (Topical) Pimecrolimus (AG) (Topical) Tacrolimus (Topical) Pimecrolimus (Topical) Eucrisa (Topical) Dupixent Syringe (Subcutaneous) Dupixient Pen (Subcuta neous) 	PA	Υ

^{*}AHCCCS P&T determines whether or not to permit grandfathering (continued use of a non-formulary medication). If grandfathering is not permitted, members will need to switch to the preferred formulary alternative and a new prescription may be required. (See AHCCCS Policy 310-V)

Formulary and Pharmacy Updates Effective January 1, 2023 Page 2 of 2

** Prior Authorization (PA), Step Therapy (STEP), Quantity Limit (QL), Age Restriction (AGE), Authorized Generic (AG) If you have any questions, please contact the Pharmacy Prior Authorization at 602-778-1800 (Options 5, 5).

Thank you!